Breaking News
News

Neotal HBV vaccine reduces liver cancer risk

Beijing, December 31: Neotal hepatitis B vaccition can significantly reduce the risk of liver cancer and other liver diseases in young adults, says a study. The findings are based on long–term outcomes from a controlled trial of neotal HBV (hepatitis B virus) vaccitions that were conducted between 1983 and 1990 in Qidong County, a rural area in Chi with a high incidence of HBV–related primary liver cancer (PLC) and other liver diseases. “Neotal HBV vaccition significantly decreased HBsAg seroprevalence in childhood through young adulthood and subsequently reduced the risk of PLC and other liver diseases in young adults,” said Chunfeng Qu from the Chinese Academy of Medical Sciences’ Cancer Institute and Hospital. HBsAg seroprevalence is an indicator of hepatitis B virus infection. In this study, 41 rural towns (including 77,658 newborns) were randomised to the intervention (HBV vaccition for all newborns) or control (no vaccition) groups. Two–thirds of the control group participants received a catch–up vaccition at age 10–14 years. Based on survey data collected in 1996–2000 and 2008–2012 on HBsAg seroprevalence, the researchers concluded that the efficacy of the catch–up vaccition on HBsAg seroprevalence in early adulthood was weak compared to neotal vaccition (21 percent versus 72 percent).  (IANS)

About the author

Ankur Kalita

Add Comment

Click here to post a comment

Click Here To Play